NeuroSense Therapeutics Ltd. is developing treatment for patients with debilitating neurodegenerative diseases.The company's lead product, PrimeC, is a novel oral formulation in clinical trials to treat amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease, and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics was incorporated in 2017 and is headquartered in Herzliya, Israel.
What is Neurosense Therapeutics's quote symbol?
What is the 52 week high and low for Neurosense Therapeutics (NASDAQ: NRSN)?
How much is Neurosense Therapeutics stock worth today?
How much is Neurosense Therapeutics's stock price per share?
What is Neurosense Therapeutics's Market Cap?